Are One Track Pony Clusters Sustainable? The Israeli Biotechnology Industry by Breznitz, Shiri M.
 
 
 
 
INDUSTRY STUDIES ASSOCATION 
WORKING PAPER SERIES 
 
 
Are One Track Pony Clusters Sustainable? 
The Israeli Biotechnology Industry 
 
By 
 
Shiri M. Breznitz 
School of Public Policy 
Georgia Institute of Technology 
Atlanta, GA 30332 
shiri.breznitz@pubpolicy.gatech.edu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2009 
Industry Studies Association 
Working Papers 
 
WP-2009-06 
http://isapapers.pitt.edu/ 
ARE ONE TRACK PONY CLUSTERS SUSTAINABLE?  
THE ISRAELI BIOTECHNOLOGY INDUSTRY 
Shiri M. Breznitz 
School of Public Policy 
Georgia Institute of Technology 
 
ABSTRACT 
 
Industrial clusters are deemed to be critical for industrial development and local economic 
growth. These concentrations include related industries which may collaborate as well as 
compete with each other.  One of the factors behind the success of clusters is the combination 
of a large number of companies, of various sizes, working along many stages of production. The 
availability of different suppliers, human resources from competing companies or local 
universities as well as customers promotes the growth of a cluster. However, in the last two 
decades, many industrial districts have become more specialized in particular stages of 
production. Considering the above factors for cluster success, important questions rise: what is 
the danger of specialization? Exactly how narrow a stage of production is too narrow for cluster 
sustainability?  This paper examines an innovation based cluster, the biotechnology industry in 
Rehovot, Israel.i
 
 This industrial district, which is the largest biotechnology cluster in Israel, is 
based on innovative companies, many spun out of university research. This paper used both 
quantitative and qualitative research methods. The dynamic of the industry was investigated 
using qualitative methods through field research including site visits and interviews. This paper 
argues that while innovation can be the base of an industry, and R&D is the base of several 
successful industrial districts around the world, it may not be sufficient for local economic 
growth and sustainability.  
 
                                                 
 
                                                 
i The city of Rehovot locates inland, half an hour from Tel Aviv.  In the city we can find the Weitzman Institute and 
the Hebrew University’s agriculture department. In this paper the Rehovot cluster will include also the firms 
located in “Kiryat Weizmann”, which was built in Nes Tziona, Rehovot's smaller neighbour.  The two clusters are 
closely located, and are less than five minutes apart. 
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Introduction 
 Industrial clusters or districts deem to be critical for industrial development and local 
economic growth. Industrial clusters are defined as a geographical concentration of related 
firms and organizations from the same industry (BRAUNERHJELM and FELDMAN, 2006). 
These concentrations include related industries which may collaborate as well as compete 
with each other (LAZONICK, 1993, PORTER, 1990, CASPER, 2007). One of the factors 
behind the success of clusters is the combinations of a large number of companies, of various 
sizes, working along many stages of production (PIORE and SABEL, 1984, MARKUSEN, 
1996, SAXENIAN, 1994). Another important factor for cluster success is learning combined 
with upstream and downstream innovation (COOKE and MORGAN, 1998). 
 In the last two decades, many industrial districts become more specialized in 
particular stages of production. Two related processes contribute to this specialization: 
globalization and fragmentation of production. With globalization firms can tap into 
resources and international markets, allowing them to increase productivity and reduce costs. 
With fragmentation of production, where certain stages of production are conducted in 
particular locations, we find “rising specialization in particular stages of the product 
manufacturing chain and rising international interfirm trade in components” (BREZNITZ, 
2007) .Examples of the globalization and fragmentation of production can be seen in R&D 
clusters such as the ICT industry in Israel or biotechnology in Cambridge, Massachusetts and 
Cambridge, UK; or biotechnology manufacturing clusters such as biotechnology in Denmark 
and Ireland.  
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 Cluster development and sustainability are based on many factors including the 
availability of resources and markets. However, successful clusters have shown that  
knowledge transfer is one of the most important factors, and can be viewed in clusters 
through the networking of individuals and firms. Formal meetings arranged through industrial 
associations as well as and informal meetings at local coffee shops and restaurant contribute 
to knowledge exchanges and thus cluster development (BREZNITZ and ANDERSON, 2006, 
FLORIDA, 1995, KEEBLE and WILKINSON, 2000). Moreover, firm collaboration and 
competition are important factor for cluster development. The availability of different 
suppliers, humane resources from competing companies or local universities as well as 
customers promotes the growth of a cluster (COOKE, 2001, COOKE, 2002, CORIAT and 
WEINSTEIN, 2002, KENNEY, 1986, LAZONICK, 1993, PORTER, 1990). Considering 
these factors, important questions rise: what is the danger of specialization? Exactly how 
narrow a stage of production is too narrow for cluster sustainability?  
 These questions are vital on both the theoretical and policy levels. On the theoretical 
level, current economical changes require us to re-conceptualize industrial clusters; to 
understand their composition and whether we should continue and rely on their ability to 
generate economic growth.  On the policy level, if industrial clusters have changed their role 
and their ability to contribute to local economies, changes in policy must follow to assure that 
we maximize our return from public investments. 
 An analysis of a specialized cluster will allow us to better understand the advantages 
and disadvantages for focusing on a specific stage of production or product. This paper 
examines an innovation based cluster, the biotechnology industry in Rehovot, Israel.i This 
industrial district, which is the largest biotechnology cluster in Israel, is based on innovative 
companies, many spun out of university research. Majority of companies in the cluster are 
small and focus on R&D. Following a series of in-depth interviews and site visits, this study 
investigates whether a cluster of young research companies can become the bases of 
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industrial growth and bring economic sustainability to a region. This paper argues that while 
innovation can be the base of an industry, and R&D is the base of several successful 
industrial districts around the world, it may not be sufficient for local economic growth and 
sustainability. To achieve further development and regional growth companies require 
additional factors in the form of other companies in different stages of production, supported 
by policy, funding, and expertise. Hence, industrial growth and sustainability may require a 
wider base of production. In the case of the Rehovot cluster, the focus of the biotechnology 
companies on research and development of one product, without manufacturing or sales, did 
not lead to a development of an entire industry and jeopardizes the sustainability of the 
cluster. 
 
Understanding innovation as a factor in regional economic development 
 “Increasingly clusters—regional concentrations of related firms and organizations—
are perceived to be the locus of economic growth” (BRAUNERHJELM and FELDMAN, 
2006, p. 1). The importance of these agglomerated firms is their creation of an 
entrepreneurial environment in which knowledge sharing and new ideas come to life, leading 
to economic development on a regional and national level (KEEBLE and WILKINSON, 
1999, LAWSON and LORENZ, 1999, PORTER M.E, 2000, CASPER and KARMANOS, 
2003, COOKE, 2002, DOERINGER and TERKIA, 1995, BREZNITZ and ANDERSON, 
2006, LOWE and GERTLER, 2005).  
 Importantly, the basic idea behind industrial clusters is the ability to reduce cost and 
have access to factors of production. Firms choose to locate in a cluster to benefit from joint 
resources.  Employees, who are in important base of any industry, choose their work 
environment and stay in a region when there is a concentration of firms that can offer them 
job security (BREZNITZ, 2000, EATON and BAILYN, 1999). Companies share resources in 
the form of labor force and equipment and in particular employees with different experience 
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in the production chain. Young companies will seek to recruit employees from companies 
that are further along the value chain in order to benefit from their knowledge and experience. 
Mature companies will seek to recruit employees from younger firms as well as university 
graduates to benefit from any new innovation on the market (BREZNITZ et al., 2008, 
PORTER, 1990). Service providers such as accounting and venture capital firms open 
branches in areas where they can maximize service to numerous companies. Thus, new firms 
locating in a cluster enjoy access to services otherwise not available. 
 Another advantage to clustering is collaboration:  
The concentration of firms in close geographical proximity allows all  
to enjoy the benefits of large scale industrial production and of technical and 
organizational innovations which are beyond the scope of any individual 
firm.          (KEEBLE and WILKINSON, 1999, p. 297)      
 
The proximity of firms allows them to learn and cooperate with each other. Particularly, we 
find collaborative efforts in which many firms contribute different segments of the final 
product. In their book,  The Second Industrial Divide Piore and Sable describe the optimal 
region where small to medium size firms cooperate in matter of research and development, 
workforce, product design, manufacturing, and marketing (PIORE and SABEL, 1984).  
 Such collaboration contribute to the innovation base of the region (SAXENIAN, 
1994, PORTER, 1990). Existing theories identify innovation as one of the main factors 
contributing to regional economic success. Systems of innovation and innovative milieu 
theories both focus on the importance of knowledge transfer, innovation, and collaboration as 
the basis for economic growth (COOKE, 2002, KEEBLE, 1998, KEEBLE and 
WILKINSON, 1999, LAWSON and LORENZ, 1999, NELSON, 1993, NELSON and 
NELSON, 2002, ETZKOWITZ, 1995). Importantly, different combinations of actors will 
create diverse learning and development avenues that will influence the innovation process. 
The rapid technological changes in the economy demand that different players support each 
other in knowledge sharing and learning in order to keep innovating.  
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 Cooke and Morgan (1998) claim that some regions with innovative organizations, 
connected through joint research programs, policies, and social networks in an institutional 
milieu, “combine learning with upstream and downstream innovation capability” (ibid. 71), 
making them regional innovation systems. This represents a regionally based innovative 
network connecting universities, colleges, and research institutes. In these regions, companies 
are able to access and test knowledge more easily. In regional systems of innovation, 
knowledge becomes the “most strategic resource and learning the most important process” of 
economic development; this is also true for the learning region theory (LUNDVALL, 1994). 
In order to create economic development, high-level innovation and production processes 
need to be maintained in the region at all times. These processes are achieved through 
constant learning and training for employees, an intra-firm learning process that spills over to 
regional learning, have a direct impact on the success of the cluster (CARLSSON et al., 
2002).  
 Clusters differ from one another by their composition and their achievement in 
industrial competitiveness (BRAUNERHJELM and FELDMAN, 2006). Mainly, there are 
two kinds of clusters. In one, we find many small to medium size enterprises collaborating in 
Production Networks (BREZNITZ, 2007). In these clusters products maybe the final 
manufactured goods or component. Moreover, these clusters are based on supplier customer 
relationships, each producing one part of the final product (PIORE and SABEL, 1984, 
BREZNITZ, 2007). In others, different sizes of firms, each working on their own stage of 
production, enjoy the benefit of locating in proximity to other firms in the same industry to 
benefit from resources in the form of labor force, equipment, and knowledge transfer 
(PORTER, 1990, HARRISON, 1992, MARKUSEN, 1985).  
 Increasingly we find more of the specialized clusters , such as the “Fabless design 
houses” who focus on a particular stage or stages of production (BREZNITZ, 2007, 
GEREFFI, 1994, STURGEON, 2002). These clusters dedicate themselves to one part of the 
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production process; i.e. R&D, manufacturing, design, etc.  Hence, specific stages of 
production, including R&D, are found in specific regions around the world. We find 
fragmented clusters in different industries including biotechnology. Some examples can be 
seen in the manufacturing biotechnology clusters in Ireland and Denmark, and the R&D 
biotechnology clusters in Cambridge Massachusetts and Cambridge, UK. Similarly, we find 
ICT R&D cluster in Israel and a software outsourcing cluster in India, which works on part of 
projects for other software companies around the world. 
 In summary, cluster literature highlights the importance of diversity and depth of 
activities within the same cluster as a measure of industrial growth and sustainability. In 
particular, scholars highlight variety in firm size, stage of production, and the importance of 
knowledge transfer and collaboration.  
 
Research Framework 
 This study seeks to understand whether specialized clusters are sustainable. In 
particular, this paper focuses on an important question: what is the danger of specialization? 
Exactly how narrow a stage of production is too narrow for cluster sustainability?  It does so 
by examining one case study, the biotechnology industry in Rehovot, Israel.  
 Biotechnology is a particularly appropriate subject for this paper. Biotechnology is a 
“new science,” with the earliest companies established in the late 1970s and the industry 
relying on the newest research. The Most of this basic research, not a developed product, is 
found in universities laboratories. Moreover, due to high costs and the length of time between 
research and development, majority of young biotechnology firms have one to two products 
and focus on R&D. However, MNC’s and large corporations carry out multiple parts of the 
production chain including development, manufacturing, marketing, and sales. Thus, it is 
typical to find networking and technology transfer between individuals and between firms in 
biotechnology clusters; making the industry especially suited to be studied as a specialized 
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cluster. Moreover, the length it takes to progress in the production cycle of biotechnology 
tends to make this industry specialized and hence perfect fit for this study. 
 The number of firms in the cluster makes Israel and the Rehovot cluster a particularly 
appropriate subject for this paper. Out of the 129 biotechnology firms and 74 pharmaceutical 
companies in Israel, thirty biotechnology firms are located in the Rehovot cluster. The 
relative small number of companies, compare to Cambridge Massachusetts or Cambridge 
UK, allows us to examine the entire industry and learn exactly how many companies are at 
which product development stage as well as follow company connections and collaborations. 
The fact that Israel successfully developed a leading ICT cluster, leads us to believe that its a 
fertile ground for cluster generation and development. 
  This paper used both quantitative and qualitative research methods. Quantitative 
methods provide the foundation of the research with information on the industry’s growth 
rate, emergence of new companies, and their specialization level. The dynamic of the 
industry was investigated using qualitative methods through field research including site 
visits and interviews.  Eighteen open-ended interviews were conducted with the life science 
industry in Israel. Interviews were conducted with company executives, researchers, 
government representatives, VC’s, and technology transfer offices. Majority of the interviews 
were done in the cities of Ness-Ziona and Rehovot. 
 
 
The Life Science Industry in Israel 
 According to the Israeli Life Science Industry Association (ILSI) there are 500 life 
science companies in Israel. This includes 285 companies in Medical devises, 129 in 
biotechnology, 74 in pharmaceuticals, and 21 companies in Agbiotech. About 22% of these 
companies were established before 1995, with Teva, the oldest Israeli Pharmaceutical 
company, established in 1901.  
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Figure 1: Israel Life science industry by sector. Source: ILSI, 2007. 
Israel’s life science industry is ranked eight in the world by number of companies (ERNST & 
YOUNG, 2005). However, the industry is very young. 45% of the companies were 
established in the last seven years.  
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Figure 2: Israel’s life science industry by companies. Source: ILSI, 2007. 
 
 Israel is one of the world leaders in life sciences research. Its universities are ranked 
as some of the world’s top universities, particularly in sciences (the Hebrew University and 
the Technion), and in Biological sciences (the Hebrew University and Tel Aviv University). 
The academic capability in life sciences is represented in the amount of life sciences 
companies. Many of these companies were founded by academics and are located in 
proximity to academic institutes (THE TIMES HIGHER EDUCATION, 2004). Similarly to 
other biotechnology firms and especially biotechnology spinouts, these firms are small to 
medium size and are R&D intensive (NEED TO ADD CITATION). 
 Funding life science companies, especially at the seed stage is difficult all around the 
world. According to the 2005 Ernest & Young report, the venture capital industry had moved 
from funding biotechnology companies at the first round in 2000, to funding mainly later 
stage companies in 2004 (ERNST & YOUNG, 2005).  This trend did not skip the Israeli 
market. In general the Israeli VC industry does not invest in the early stage companies. Thus, 
Israeli biotechnology firm suffer from funding shortage. This shortage is especially felt at two 
 10
stages of the production cycle: at the early stage, moving the invention from an academic 
setting to the industry and at the bridge, and prior to the proof of concept, before you can 
show a product to investors. Much of the funding of early stage life science companies 
arrives from the Office of the Chief Scientist (OCS) in the Ministry of Trade and Industry. 
The Chief Scientist's budget for 2005 was NIS 1.2 Billion (approx. US $275 million), 
compared with NIS 1.3 Billion in 2004. This continues the downward budget trend of recent 
years: from NIS 1.6 Billion in 2003 and NIS 1.8 Billion in 2002. In comparison, the US 
Federal agencies spent $106.5 billion in support for R&D in FY 2005. 
 The OCS funds the technological incubators in Israel. Today there is only one life 
sciences incubator in Jerusalem, Bioline. However, Bioline is a project based incubator, it 
does not develop companies. Although the governmental support for a life science company 
at an incubator is double the amount of any other company, incubators are not inclined to 
take on a biotechnology company. The time, knowledge, and equipment required for such 
development are more complex and not necessarily available with in the existing funding 
base. Incubators that do take biotechnology companies do not have the resources to mentor 
and support them. Mostly, these companies have to work alone to make the connections and 
recruit their funding.  
 
The Rehovot Cluster 
 The Rehovot Cluster is one of the largest biotechnology clusters in Israel representing 
thirty out of a total of 129 companies in Israel. It is situated in the center of Israel in close 
proximity to the Weitzmann Institute and the Hebrew University’s Department of 
Agriculture, in the town of Rehovot, twenty minutes drive from Tel-Aviv. This study finds 
that while on one hand the Rehovot cluster incorporates distinctive cluster characteristics it is 
missing many others. The lack of some of these factors questions the sustainability of this 
cluster. 
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 There are qualified employees in the cluster, mostly graduates from both the 
Weitzmann Institute and the Hebrew University, and like in many clusters, we can see 
movement of employees between companies. Furthermore, these employees share common 
background and together create a social and technological network, sharing information and 
equipment as needed. Numerous companies’ founders are graduates of one of the 
departments or of the former incubator at Weizmann. Many still hold close connections with 
their former departments and peers at Weitzmann and the Hebrew University. Some 
companies that spun-out of these institutes require assistance with equipment, consult with 
faculty, and use the universities’ libraries. Some of these connections are official but most 
rely on the generosity and curiosity of the faculty.  
People are moving between companies. You stay friends (from academia) and 
you transfer knowledge and help each other. There is knowledge transfer with 
the academic departments but its informal, between people, not necessarily 
between managements.   Interview with a biotechnology executive A 
 
Thus, faculty interest in the company, both financially and academically, leads to provision of 
services for young start-ups. A third cluster characteristic is the availability of a variety of 
industry suppliers and some Contract Research Organizations (CROs). The large number of 
biotechnology firms allows and attracts suppliers to locate in the region, providing daily 
services.    
 On the other hand, the Rehovot cluster is missing some cluster advantages. More 
importantly, it is missing many of the factors that we listed as important to cluster success, in 
particular diversity. Since national and regional resources are directed solely to R&D, in an 
attempt to duplicate the success of the Israeli ICT industry, the industrial concentration of 
companies in the Rehovot cluster is highly specialized and focuses on the R&D. 
 
 The Rehovot cluster has skilled employees in the research stage, many of which are 
new graduates from the local research institutions. Moreover, these institutions provide the 
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base from which many of these companies draw new knowledge, expertise, equipment, and 
employees. While academically Israel’s scientists are ranked as ones of the best in the world, 
the industry lacks employees with industry experience, especially in the management, 
development, and manufacturing levels. Partly, this is due to the development stage of the 
industry in Israel. Only 12% of companies are at the clinical stage, while majority of 
companies are at the seed stage (ISRAEL LIFE SCIENCE INDUSTRY, 2007).  There are 
only a few companies in Israel that succeeded in getting a product from the research stage to 
production, such as Teva, BTG, and XTL.  Moreover, there is hardly a representation of 
MNC’s in the life science industry in Israel. The lack of mature companies creates two major 
hurdles for the life science industry in Israel. One, there are not enough companies that can 
transfer their knowledge in later stages of production to younger companies in the country, 
and contribute to the development of the industry. Secondly, shortage of mature companies 
leads to a shortage of skilled employees at all levels of the production chain. Both these 
issues have a direct impact on the ability of the industry to further develop (BREZNITZ and 
ANDERSON, 2006, PORTER, 1990, CASPER and KARMANOS, 2003).  
 This study confirms that the Rehovot cluster has a crucial problem with later stages of 
production.  The cluster does not have enough qualified managers or employees with 
expertise and knowledge required by biotechnology companies in the different stages. Many 
of the employees, who are coming directly from academia, lack the knowledge and “know-
how” of working in an industrial laboratory. Companies face these problems in several ways: 
some chose to invest time and personnel in the training of new workers, others choose to 
collaborate with international companies or build their development stages in other countries, 
leaving only the research phase in Israel.  
There is a lack of experience in development and manufacturing. Today, our 
company has two employees who are working for [a bigger company] in order 
for them to gain the knowledge we need.       
              Interview with Biotechnology executive B. 
 13
Humane resource in science – excellent. In business very few have the 
knowledge. In our company we have two people that moved to this industry 
from ICT.                Interview with Biotechnology executive A. 
It is hard to find people that have seen a product through all stages of 
production. Most people have only the clinical base. The academic background 
is important but it is just the base. We are missing people that know how to 
develop. We need people with industry experience.    
     Interview with Biotechnology executive C. 
 Knowledge transfer in the Rehovot cluster, which in other clusters is mainly achieved 
through social networks, is based on direct and informal relations with either the faculty or 
alumni of the Weitzmann Institute or the Hebrew University’s Department of Agriculture. 
There are minimal formal relations between companies and between companies and the 
academic institutes. Mostly, connections with the academic institutes are with a researcher or 
faculty with whom the founder or one of the company’s researchers has past connections. 
Thus, there are hardly formal connections, contract based, between companies and the 
academic institutions. As a result, the social networks in this cluster are linear and are based 
on one connection per company. Importantly, the lack of mature companies does not provide 
another way to resolve this issue. 
 Israeli funding for biotechnology, both public and private, directs the industry towards 
R&D. Governmental funding for the industry arrives from the Office of the Chief Scientist 
(OCS). As it is, the office funds in general high technology companies in the R&D stages. 
Moreover, due to the nature of government investment in R&D there is no investment in 
Contract Research Organizations (CROs) that can advance companies in particular research 
stages. Hence, with the lack of mature companies that can train or transfer knowledge on later 
stages of production, it leaves the companies to focus on R&D. As was explained in the 
previous section, there is hardly any VC investment in the Israeli life science industry. 
 Direct investment by the Chief Scientist is as well directed to basic research. The 
OCS has very little investments directed to the life science industry in general. Only one 
program: “Nofar” invests particularly in biotechnology at $100,000 per project. This program 
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funds biotechnology projects at academic institute that collaborate with industry. The OCS 
funds 90% and industry funds 10% of the project. In comparison, just the NIH, in the US, 
invests over $27 billion annually in medical research. Hence, there is no funding for a new 
start-up that does not have a project with a university and there is no funding for equipment. 
The OCS funds only half a project. You still have to find funding for the other 
half. They ask for a lot of paperwork and place many restrictions on how and 
what is needed to spend the funding.      Interview with company executive D. 
 Funding through the OCS is available only for R&D. Thus, Contract Research 
Organization (CRO), an organization that offers clients a wide range of pharmaceutical 
research services which are vital to the biotechnology industry, are not eligible for funding. 
Services offered by CROs include: product development and formulation, clinical trial 
management (preclinical through phase IV), central laboratory services for processing trial 
samples, data management services, and many other complementary services. CROs can 
offer their clients the experience of moving a new drug from its conception to FDA 
marketing approval without the drug sponsor having to maintain a staff for these services, 
which often have limited duration. Thus, creating a shortage of CROs for the industry and 
requiring many of the companies to look for services abroad.  Moreover, companies at the 
technological incubators do not have the financial capabilities to pay for services (animal 
testing, proteins, etc), and their governmental funding does not allocates funding for services 
and/or equipment.  
 In summary, existing theories view firms’ diversity and collaboration in a cluster as 
the base for innovation and regional economic growth and sustainability. Importantly, the 
literature reviles that further development of each cluster requires a variety of players, in 
different stages of production. This study’s analysis of the Rehovot biotechnology cluster in 
Israel finds a growing industry. However, this cluster consists of small to medium size 
enterprises, majority of which are in their research stages. There are almost no companies in 
their development, manufacturing, marketing and sales stages in the cluster, resulting in 
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shortage of qualified employees for later stages of production and experienced managers. 
Moreover, the cluster lacks the networking and communication that is typical to industrial 
districts. The companies base their survival through their product development with very 
limited resources, leaving them with little opportunity to network. Due to these difficulties, 
many companies focus on “the one molecule company” strategy, i.e. companies that have 
developed only one product based on one molecule with a strategy to sell the molecule at the 
proof of concept stage. Thus, these companies do not even plan on getting to the development 
or manufacturing stages. All future products will be sold to multi national companies 
overseas, where they would create new jobs in production and marketing instead of in Israel. 
 
Conclusions  
 Biotechnology clusters can be found around the world. Successful cluster are 
characterized with many kinds of companies, in different sizes, product specialization, and  
stage of production. Hence, the clusters encompass a variety of skills and knowledge that are 
transferred within the cluster through social networks. Germany, France, UK, Ireland, and 
Denmark, all have been developing regional biotechnology clusters (CASPER and 
MATRAVES, 2003, LEMARIÉ et al., 2001, ERNST & YOUNG, 2007). Unlike the Israeli 
cluster approach to promote R&D, these concentrations of firms focus on bringing life-
science multi national companies to their region. Ireland and Denmark promoted the 
availability of green fields and policy incentives to draw in multi nationals that are interested 
in opening new manufacturing facilities. For these countries, manufacturing creates a wide 
base of good paying jobs but also brings the know-how to their region. 
 In France, UK, and Germany, many multi nationals chose to open R&D facilities 
tapping into the local knowledge base and expertise, and especially the availability of human 
resources with experience in pharmaceuticals. Hence the new clusters are characterized by 
many firms, from a diverse background, in different stages of production, collaborating and 
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competing in a growing industrial cluster, which allows them to continue to develop and 
result in sustainable clusters  (ERNST & YOUNG, 2007). 
 The biotechnology industry has a global market. Building on Israel’s academic 
strength can lead to positioning Israel as a leader in life sciences. However, with the lack of 
R&D tax incentives, experience labor force, and mature companies, this industry is facing 
extreme developmental issues. As we have seen from the Rehovot Science Park, companies 
are struggling to survive. Unlike the Israeli ICT industry life science companies require large 
sums of funding especially from public source, which are currently not available. Moreover, 
while there are mature ICT companies in Israel there are very few pharmaceutical companies 
and no mature biotechnology firms. Thus, there is a lack of qualified labor force that can lead 
this industry in the upcoming steps of the production chain. Hence, this paper finds that the 
narrow base of the Rehovot biotechnology cluster may not be sustainable and the survival of 
firms in this cluster is in danger.  
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i The city of Rehovot locates inland, half an hour from Tel Aviv.  In the city we can find the Weitzman Institute 
and the Hebrew University’s agriculture department. In this paper the Rehovot cluster will include also the firms 
located in “Kiryat Weizmann”, which was built in Nes Tziona, Rehovot's smaller neighbour.  The two clusters 
are closely located, and are less than five minutes apart. 
